DK3484475T3 - 1-methylnicotinamid til behandlingen af kardiovaskulær sygdom - Google Patents
1-methylnicotinamid til behandlingen af kardiovaskulær sygdom Download PDFInfo
- Publication number
- DK3484475T3 DK3484475T3 DK17743399.2T DK17743399T DK3484475T3 DK 3484475 T3 DK3484475 T3 DK 3484475T3 DK 17743399 T DK17743399 T DK 17743399T DK 3484475 T3 DK3484475 T3 DK 3484475T3
- Authority
- DK
- Denmark
- Prior art keywords
- methylnicotinamide
- treatment
- cardiovascular disease
- cardiovascular
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662363712P | 2016-07-18 | 2016-07-18 | |
| PCT/IB2017/054293 WO2018015861A1 (en) | 2016-07-18 | 2017-07-16 | 1-methylnicotinamide for the treatment of diseases associated with c-reactive protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3484475T3 true DK3484475T3 (da) | 2023-11-27 |
Family
ID=59399457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17743399.2T DK3484475T3 (da) | 2016-07-18 | 2017-07-16 | 1-methylnicotinamid til behandlingen af kardiovaskulær sygdom |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190282560A1 (da) |
| EP (1) | EP3484475B1 (da) |
| JP (1) | JP2019521160A (da) |
| CN (1) | CN109562108A (da) |
| AU (1) | AU2017298648B2 (da) |
| CA (1) | CA3030805A1 (da) |
| DK (1) | DK3484475T3 (da) |
| ES (1) | ES2967074T3 (da) |
| FI (1) | FI3484475T3 (da) |
| MX (1) | MX389845B (da) |
| PL (1) | PL3484475T3 (da) |
| RU (1) | RU2744615C2 (da) |
| WO (1) | WO2018015861A1 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020115765A1 (en) | 2018-12-05 | 2020-06-11 | Celagenex Research (India) Pvt. Ltd. | Novel synergistic composition comprising sirt1 and ampk activators for treating metabolic syndrome |
| CN112294786A (zh) * | 2019-08-01 | 2021-02-02 | 深圳大学 | 一种含乙胺丁醇与他汀类药物的抗结核组合药物 |
| WO2021205341A1 (en) | 2020-04-07 | 2021-10-14 | Pharmena S.A. | 1-methylnicotinamide for the prevention/treatment of inflammatory airway diseases |
| WO2022047730A1 (en) * | 2020-09-04 | 2022-03-10 | Shanghai Pharmaceuticals Holding Co., Ltd. | Methods to treat inflammatory bowel disease |
| WO2022061234A2 (en) * | 2020-09-21 | 2022-03-24 | The Regents Of The University Of California | Immunological effects of metabolites |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT131118B (de) | 1929-04-19 | 1933-01-10 | Ig Farbenindustrie Ag | Verfahren zur Darstellung von N-Methylpyridiniumchlorid. |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3614408A (en) | 1969-02-20 | 1971-10-19 | British Petroleum Co | Waveform analyzing system, particularly for chromatographs, wherein the waveform is integrated between selected peaks and valleys |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4115390A (en) | 1977-08-19 | 1978-09-19 | Nardi John C | Method for the preparation of 1-alkyl pyridinium chlorides |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US7030152B1 (en) | 1997-04-02 | 2006-04-18 | The Brigham And Women's Hospital, Inc. | Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
| PL364348A1 (en) * | 2004-01-12 | 2005-07-25 | PHARMENA Sp.z o.o. | Application of quaternary pyridine salts as vessel protection agent |
| WO2006024545A1 (en) * | 2004-09-03 | 2006-03-09 | Stichting Voor De Technische Wetenschappen | Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes |
| AU2006329564A1 (en) * | 2005-07-11 | 2007-07-05 | Pharmena North America Inc. | Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative |
| EP1963270B1 (en) * | 2005-12-09 | 2009-08-05 | Cerecon AG | Quaternary 3 -amido, n-methylpyridinium salts as anti -inflammatory agents |
| PT2026651E (pt) * | 2006-03-08 | 2013-06-04 | Cortria Corp | Terapia combinada com inibidores cox não selectivos para prevenir lesões gástricas relacionadas com a cox |
| PL381862A1 (pl) * | 2007-02-28 | 2008-09-01 | Trigendo Spółka Z Ograniczoną Odpowiedzialnością | Zastosowanie związków pirydyniowych i sposób leczenia |
| US20090118225A1 (en) * | 2007-09-28 | 2009-05-07 | Cortria Corporation | 1-Methyl Nicotinamide and Derivatives for Treatment of Gastric Injury |
| PL2211858T3 (pl) * | 2007-10-12 | 2015-06-30 | Politechnika Lodzka | Zastosowanie czwartorzędowych soli pirydyniowych do hamowania przerzutów nowotworowych |
| EP2285379A4 (en) * | 2008-05-06 | 2011-11-02 | Cortria Corp | ANALOGUES OF 1-METHYLNICOTINAMIDE |
| CA2777800C (en) * | 2009-10-15 | 2019-11-12 | Crescendo Bioscience | Biomarkers and methods for measuring and monitoring inflammatory disease activity |
| PL226999B1 (pl) * | 2013-06-11 | 2017-10-31 | Univ Jagiellonski | Azotan (III) 3 -karbamoilo -1-metylopirydyniowy, sposób jego otrzymywania izastosowanie |
-
2017
- 2017-07-16 DK DK17743399.2T patent/DK3484475T3/da active
- 2017-07-16 ES ES17743399T patent/ES2967074T3/es active Active
- 2017-07-16 CA CA3030805A patent/CA3030805A1/en active Pending
- 2017-07-16 MX MX2019000721A patent/MX389845B/es unknown
- 2017-07-16 EP EP17743399.2A patent/EP3484475B1/en active Active
- 2017-07-16 WO PCT/IB2017/054293 patent/WO2018015861A1/en not_active Ceased
- 2017-07-16 JP JP2019502239A patent/JP2019521160A/ja active Pending
- 2017-07-16 US US16/318,257 patent/US20190282560A1/en not_active Abandoned
- 2017-07-16 AU AU2017298648A patent/AU2017298648B2/en active Active
- 2017-07-16 RU RU2019104343A patent/RU2744615C2/ru active
- 2017-07-16 FI FIEP17743399.2T patent/FI3484475T3/fi active
- 2017-07-16 CN CN201780048301.3A patent/CN109562108A/zh active Pending
- 2017-07-16 PL PL17743399.2T patent/PL3484475T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL3484475T3 (pl) | 2024-03-11 |
| RU2744615C2 (ru) | 2021-03-11 |
| AU2017298648B2 (en) | 2023-05-11 |
| US20190282560A1 (en) | 2019-09-19 |
| AU2017298648A1 (en) | 2019-01-31 |
| RU2019104343A3 (da) | 2020-09-17 |
| ES2967074T3 (es) | 2024-04-25 |
| JP2019521160A (ja) | 2019-07-25 |
| MX389845B (es) | 2025-03-20 |
| FI3484475T3 (fi) | 2023-12-12 |
| WO2018015861A1 (en) | 2018-01-25 |
| EP3484475A1 (en) | 2019-05-22 |
| RU2019104343A (ru) | 2020-08-18 |
| MX2019000721A (es) | 2019-06-10 |
| CN109562108A (zh) | 2019-04-02 |
| CA3030805A1 (en) | 2018-01-25 |
| EP3484475B1 (en) | 2023-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3501542T3 (da) | Esketamin til behandling af depression | |
| DK3570844T3 (da) | Azolopyrimidin til behandlingen af kræftrelaterede lidelser | |
| DK3192902T3 (da) | Fremgangsmåde til fremstilling af graphenholdige viscosefibre | |
| DK3325443T3 (da) | Fremgangsmåde til fremstilling af pridopidin | |
| DK3326641T3 (da) | Rna-holdig sammensætning til behandling af tumorsygdomme | |
| IL264143B (en) | Processes for preparing olaparib | |
| DK3288581T3 (da) | Fremgangsmåde til behandling af cancer | |
| DK3439635T3 (da) | Formuleringer til behandling af fast tumor | |
| DK3096741T3 (da) | Fremgangsmåde til fremstillingen af hybridosomer | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3390390T3 (da) | Bipyrazolylderivater egnede til behandling af autoimmunsygdomme | |
| DK3174858T3 (da) | Fremgangsmåde til fremstilling af pyrazoler | |
| DK3524255T3 (da) | Sammensætning til behandling af acne | |
| DK3503890T3 (da) | Anvendelse af pridopidin til behandling af dystonier | |
| DK3324824T3 (da) | Fremgangsmåde til behandling af binokulare dysfunktioner | |
| DK3280408T3 (da) | Fremgangsmåde til fremstilling af dicycloplatin | |
| DK3331610T3 (da) | Midler til anvendelse til behandling af gliom | |
| DK3307267T3 (da) | Behandling af multipel sklerose | |
| DK3261661T3 (da) | Menotropin til behandling af infertilitet | |
| DK3468604T3 (da) | Farmaceutiske kombinationer til behandling af cancer | |
| DK3585808T3 (da) | Modificerede serpiner til behandlingen af bradykinin formidlet sygdom | |
| DK3302573T3 (da) | Sammensætning til behandlingen af hjernelæsioner | |
| DK3368044T3 (da) | Behandling af hepatisk steatose-relateret oligo-ovulation | |
| DK3297619T3 (da) | Terapeutiske anvendelser af L-4-chlorkynurenin |